CME Grand Rounds for Oncologists and Surgeons

IMER Regional Meeting

Community Oncology Clinical
Debates in Breast Cancer

Click here to request this program for your organization.
Person Requesting Form:
Contact name/administrative representative (if different
from above):
Organization:
Street Address:
City:
State:
Zip:
Contact Phone:
Contact Fax:
Contact Email:
Expected Number of Medical Oncologists:
Expected Number of Surgical Oncologists:
Expected Number of General Surgeons:
Expected Number of PAs and NPs:
Expected Total Number of Attendees:
Date and time of requested program (1st choice):
Date and time of requested program (2nd choice):
Date and time of requested program (3rd choice):

Thank you. We value your feedback.

Please allow 2 business days for a response from our office.

Target Audience

This activity has been designed to meet the educational needs of community-based medical oncologists.

Purpose

To educate oncologists and surgeons on clinical debates regarding optimal chemotherapy/biotherapy for patients with early stage disease.

Program Overview

Despite remarkable progress in treatment strategies for breast cancer in recent years, several clinical debates exist regarding optimal chemotherapy/biotherapy for patients with early stage disease. This academic- and community-based grand rounds series will focus on the most pivotal ongoing debates. The curriculum is designed to foster support for clinical decision-making that effectively tailors breast cancer therapy to individual patients. Thought leader faculty will provide an overview of clinical debates, followed by one or more case studies to stimulate discussion.

Learning Objectives
  • Describe the latest clinical trial data regarding concurrent and sequential trastuzumab-based therapy including implications for the development of cardiotoxicity
  • Describe the role of taxane-containing adjuvant regimens in node-negative and node-positive breast cancer
  • Cite long-term cardiac implications related to the use of anthracyclines
Program Agenda
  • Program Overview (5 mins)
  • Clinical Debates in Early Stage Breast Cancer – Chemotherapy/Biotherapy (25 mins)
    • Case study: Is there a significant difference in cardiac toxicity between concurrent and sequential trastuzumabbased therapy? Does choice of chemotherapy affect outcomes?
    • What is the optimal duration of treatment?
    • What is known relating to cardiac injury resulting from anthracycline use?
    • Case study: Is it possible to identify specific subgroups of women who are good candidates for adjuvant taxanecontaining regimens?
  • Interactive Discussion of Debates and Case Studies (30 mins)

Jointly sponsored by:

IMER
Postgraduate Institute for Medicine

This activity is supported by an independent educational grant from sanofi-aventis U.S.

Select Other Community Oncology Clinical Debates


Additional CME Meetings on This Topic
{date} {city} {speaker}

{icon}
{location}

Faculty

William J. Gradishar, MD, FACP
(Chairperson)
Northwestern University
Feinberg School of Medicine

Kimberly L. Blackwell, MD
Duke University Medical Center

Harold J. Burstein, MD, PhD
Dana-Farber Cancer Center

Aman U. Buzdar, MD
The University of Texas M. D.
Anderson Cancer Center

Monica N. Fornier, MD
Memorial Sloan-Kettering Cancer Center

Sharon H. Giordano, MD, MPH
The University of Texas M. D.
Anderson Cancer Center

Lori J. Goldstein, MD
Fox Chase Cancer Center

Stephen E. Jones, MD
Baylor University Medical Center

Virginia G. Kaklamani, MD, DSC
Northwestern University Feinberg
School of Medicine

Hope S. Rugo, MD
University of California, San Francisco

Tiffany A. Traina, MD
Memorial Sloan-Kettering
Cancer Center

Linda T. Vahdat, MD
Weill Medical College
of Cornell University

 
Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and Institute for Medical Education & Research (IMER). PIM is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.